Exelixis, Inc. Stock News

When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share.

Shares of Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, boosted by Big Money inflows.

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as wel...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth St...

The top five biotech stocks today have several commonalities. Among them are strong ratings.

Exelixis just delivered a strong Q1 beat, raised 2025 guidance, and continues to benefit from robust Cabometyx sales and share buybacks. The company is transitioning to zanzalintinib as its next flagship drug, but pivotal trial success remains uncertain, and skepticism persists among analysts. The company has a rock-solid balance sheet with some $1.75 billion in cash and no long-term debt.

Shares of Exelixis (EXEL 17.92%) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday.

Exelixis, Inc. (NASDAQ:EXEL ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President and Chief Financial Officer P.J. Haley - Executive Vice President, Commercial Amy Peterson - Executive Vi...